PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Perampanel and levetiracetam both control SeLECTS with minor sleep differences

perampanellevetiracetamAMPA receptor antagonistanti-seizure medicationSeLECTSself-limited epilepsy with centrotemporal spikespediatric epilepsysleep architecturepolysomnographycohort studyneurology Neurology / Neuropharmacology

Background Information

PER may enhance sleep in children with SeLECTS.

Self-limited epilepsy with centrotemporal spikes (SeLECTS) often affects sleep, impacting overall management in children. Both levetiracetam (LEV) and perampanel (PER) showed effective seizure control; PER may improve sleep architecture, reducing light sleep and awakenings. While both treatments are viable, PER may offer additional sleep benefits. Longer studies are needed for conclusive evidence. LEV and PER effectively control seizures in SeLECTS; PER shows potential sleep benefits.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Yan L, Xie L, Li T, Chen J, Jiang L

Citation: Yan L, Xie L, Li T, et al. Efficacy and sleep impact of perampanel versus levetiracetam monotherapy for SeLECTS: A pilot prospective cohort study. Epilepsy & behavior : E&B. 2026;184:111228. doi:10.1016/j.yebeh.2026.111228

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.